Header Logo

Connection

Mark Pollack to Ipilimumab

Back to Details
This is a "connection" page, showing publications Mark Pollack has written about Ipilimumab.
Mark Pollack
Connection Strength
0.155
Ipilimumab
  1. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol. 2018 01 01; 29(1):250-255.
    View in: PubMed
    Score: 0.155
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.